hemophilia A

Shire writes off a shot at long-acting hemophilia drug after small study flops
Shire writes off a shot at long-acting hemophilia drug after small study flops
Endpoints
Shire
hemophilia A
SHP656
Xenetic Biosciences
clinical trials
Flag link:
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Endpoints
Pfizer
gene therapy
hemophilia
Sangamo BioSciences
SB-525
hemophilia A
Flag link:
Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.
Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.
Endpoints
Roche
hemophilia A
emicizumab
Flag link:
Roche gears up to enter loaded hemophilia A drug market
Roche gears up to enter loaded hemophilia A drug market
Medical Marketing and Media
Roche
hemophilia A
emicizumab
Flag link:
Roche Finds Safe Haven In Emicizumab
Roche Finds Safe Haven In Emicizumab
Seeking Alpha
Roche
emicizumab
hemophilia A
Flag link:
Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success
Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success
Endpoints
Roche
hemophilia A
ACE910
emicizumab
Flag link:
Hey, wait a second. What about Roche’s PhIII hemophilia A drug?
Hey, wait a second. What about Roche’s PhIII hemophilia A drug?
Endpoints
Roche
hemophilia A
Chugai
emicizumab
ACE910
Flag link:
Germany's Bayer wins U.S. FDA approval for hemophilia A therapy
Germany's Bayer wins U.S. FDA approval for hemophilia A therapy
Yahoo/Reuters
Bayer
FDA
hemophilia A
Kovaltry
Flag link:
5 Reasons Roche Thinks It Can Outclass the Competition
5 Reasons Roche Thinks It Can Outclass the Competition
Motley Fool
Roche
atezolizumab
ACE910
hemophilia A
lampalizumab
dry macular degeneration
ocrelizumab
Flag link:
Roche haemophilia drug wins fast-track FDA designation
Roche haemophilia drug wins fast-track FDA designation
Yahoo/Reuters
Roche
Genentech
FDA
fast track
hemophilia A
ACE910
Flag link:
Playing defense, Baxalta makes its case for a new hemophilia drug
Playing defense, Baxalta makes its case for a new hemophilia drug
Fierce Biotech
Baxalta
hemophilia A
BAX 855
Advate
Flag link:
3 Reasons That Biogen's Shares Could Rise
3 Reasons That Biogen's Shares Could Rise
Investopedia
Biogen
Alprolix
Eloctate
hemophilia A
hemophilia B
aducanumab
Alzheimer's disease
Flag link:
Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia
Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia
Fierce Biotech
Biogen Idec
hemophilia B
hemophilia A
hemophilia
gene therapy
Flag link:
FDA clears Baxter hemophilia A treatment
FDA clears Baxter hemophilia A treatment
Seeking Alpha
Baxter International
FDA
hemophilia A
Obizur
Flag link:
Long-acting version of Baxter's hemophilia drug succeeds in study
Long-acting version of Baxter's hemophilia drug succeeds in study
Yahoo/Reuters
Baxter International
Advate
hemophilia A
BAX 855
Flag link:
U.S. FDA approves Biogen's hemophilia A drug Eloctate
U.S. FDA approves Biogen's hemophilia A drug Eloctate
Yahoo/Reuters
Biogen
Eloctate
hemophilia A
hemophilia
Flag link:
FDA approves Biogen's hemophilia A drug Eloctate
FDA approves Biogen's hemophilia A drug Eloctate
Yahoo/Reuters
FDA
Biogen Idec
hemophilia A
Eloctate
Flag link:
Biogen's blood disorder drug succeeds in late-stage trial
Biogen's blood disorder drug succeeds in late-stage trial
Yahoo/Reuters
Biogen Idec
Biovitrum
Eloctate
hemophilia A
Flag link:
Novo reports positive results from phase 3 trial with NovoEight
Novo reports positive results from phase 3 trial with NovoEight
Reuters
Novo Nordisk
NovoEight
hemophilia A
Flag link:
FDA approves Novo Nordisk hemophilia A drug
FDA approves Novo Nordisk hemophilia A drug
Pharma Times, UK
FDA
Novo Nordisk
hemophilia A
NovoEight
Flag link: